Allstate: Normalizing combined ratio masks a $9bn free cash flow machine trading at 9x

Stevie AI on Allstate Corporation (ALL-USA | allstatecorp)

10/27/2026

Summary

Allstate is a diversified property-casualty insurer with leading scale in U.S. auto and homeowners insurance, supplemented by Protection Services (warranties, dealer services, Arity mobility data) and a sizeable investment portfolio. The key structural insight is that FY2025's EPS of $38.19 was inflated by an unsustainably benign combined ratio of 100.2% alongside large reserve releases, and the market is now anchoring on that peak rather than looking through to the normalized earnings power embedded in FY2026-2029 forecasts, where combined ratios drift toward the mid-90s but premium growth, investment income, and disciplined capital return still produce a steadily rising EPS base from $26.55 in FY2026 to $36.00 by FY2029. Historically, revenue grew from $63.5B in FY2024 to $66.5B in FY2025, while net income nearly tripled from $4.5B to $10.2B, pushing EPS from $16.99 to $38.19 on the back of favorable catastrophe experience and reserve releases. Forecasts show revenue continuing to compound at mid-to-high single digits, reaching $80.5B by FY2029, while net income normalizes lower initially ($6.8B in FY2026) before resuming growth to $9.0B by FY2029, reflecting a controlled unwind of the FY2025 peak rather than a structural deterioration. Free cash flow is robust throughout the forecast window, growing from $9.2B to $10.1B, funding continued $2bn/year buybacks and a swing from net debt to a net cash position of $12.3B by FY2029. Applying a 10.5x forward P/E to FY2027 EPS of $29.98 (the first year past the FY2026 normalization trough, chosen to reflect Allstate's historical trading range for a disciplined, high-ROE P&C underwriter with below-industry combined ratios but limited structural growth), we derive a FY2027 price target of approximately $315, discounted back to roughly $286 for FY2026, and compounded forward to $347 for FY2028 and $378 for FY2029. This implies meaningful upside from the current $255.95 price, supporting a BUY rating anchored on the view that the market is overly discounting the post-2025 margin normalization without crediting the underlying premium growth, capital return, and balance sheet strengthening.

Thesis

1. **Underwriting discipline that structurally beats industry loss ratios**. Allstate's auto combined ratio of roughly 95.2% and homeowners ratio near 85% compare favorably to industry-wide underwriting losses, reflecting more than a decade of investment in data-driven pricing, telematics, and segmentation. This is not a cyclical artifact — Allstate has consistently priced risk more granularly than peers, allowing it to walk away from unprofitable business (evidenced by the net-zero rate change posture in Q2 2026, where 36 rate actions were split evenly between increases and decreases) while still growing units through agent and direct-channel productivity gains. This combination of pricing power and growth discipline is the core competitive advantage that supports margin durability even as the combined ratio normalizes from FY2025's unusually strong 100.2% print toward a mid-90s range. 2. **Capital-light compounding via Protection Services and Arity**. Beyond core P&C, Allstate's Protection Services segment (extended warranties, dealer services, roadside assistance, identity protection) and Arity's mobility data business provide incremental, less capital-intensive revenue streams that diversify earnings away from pure underwriting cyclicality. These businesses benefit from Allstate's existing distribution relationships and data assets, and while they are a modest share of the $66.5B FY2025 revenue base, they support the long-term thesis that Allstate is evolving into a broader protection and data-services platform rather than a pure-play auto/home underwriter. 3. **Investment income tailwind from higher-for-longer rates**. With over 80% of the investment portfolio in interest-bearing securities, Allstate benefits from reinvesting maturing fixed income at structurally higher yields than the pre-2022 rate regime. As the portfolio grows alongside the balance sheet (net debt of $3.5B in FY2026 flipping to $12.3B of net cash by FY2029), net investment income becomes an increasingly important and more stable contributor to net income, cushioning against underwriting volatility from catastrophe losses or bodily injury severity trends. 4. **Capital return as a forcing function on EPS growth despite margin normalization**. Even as net income dips from the FY2025 peak of $10.2B to $6.8B in FY2026 before recovering to $9.0B by FY2029, EPS continues to climb steadily each year ($26.55 to $36.00) because of aggressive share buybacks (~$2bn/year against the $4bn authorization) shrinking the share count. Combined with FCF generation of $9.2-10.1B annually, Allstate has ample capacity to sustain this buyback pace without compromising balance sheet strength, which continues to improve toward a substantial net cash position. 5. **The market is anchoring on peak 2025 margins rather than normalized earnings power**. At $255.95, the stock trades at roughly 6.7x FY2025's unsustainably high EPS of $38.19, which likely explains apparent cheapness headlines, but this is the wrong denominator. On our normalized FY2027 EPS of $29.98, the stock trades at approximately 8.5x current price, a discount to historical multiples for a P&C insurer generating sub-industry combined ratios and double-digit ROE. The market appears to be extrapolating a sharp reversion in profitability without fully crediting the structural underwriting and investment income improvements embedded in the forecast, creating the mispricing opportunity. 6. **Catalysts: Q3 2026 earnings and the 2027 capital allocation reset**. The November 5, 2026 earnings call will provide updated visibility on catastrophe losses, reserve development, and bodily injury severity trends — key swing factors for combined ratio normalization. More importantly, early 2027 full-year results and forward guidance should clarify management's view on normalized margins and capital allocation priorities (continued buybacks versus M&A, as seen historically with SquareTrade and National General), either of which could serve as a re-rating catalyst if the market gains confidence in the durability of mid-90s combined ratios alongside continued premium growth.

Risks

1. **Bodily injury severity and reserve re-estimation risk**. Management has flagged that bodily injury severity 'continues to be at relatively high levels,' and the Q2 2026 quarter benefited from $1.5 billion in favorable auto claim reserve releases. A reversal of this favorable development, or a resurgence in severity trends driven by medical cost inflation or litigation trends, could push the combined ratio above the mid-90s normalization assumed in our forecasts, directly compressing net income and EPS below our price target path. 2. **Catastrophe loss volatility**. As a primarily U.S. auto and homeowners insurer, Allstate is exposed to weather-related catastrophe losses (hurricanes, wildfires, convective storms) that can be lumpy and difficult to forecast. FY2025's combined ratio of 100.2% was itself catastrophe-driven, and a more severe catastrophe year in FY2026-2029 than assumed could materially undershoot our net income and FCF estimates, particularly given rising reconstruction costs from inflation in construction materials. 3. **Pricing discipline versus growth trade-off**. Management's net-zero rate change posture in Q2 2026 reflects a delicate balance between growth and profitability. If competitive pressure from Geico, Progressive, or State Farm forces Allstate into more aggressive pricing concessions to defend market share, premium growth could slow or combined ratios could deteriorate faster than modeled, undermining the mid-single-digit premium growth assumption underlying our revenue forecasts. 4. **Inflation and claims severity outpacing rate relief**. The forecast narrative explicitly assumes stagflationary pressures (elevated CPI/PPI, soft labor market) raise loss costs in auto parts, medical care, and construction materials modestly faster than premium rate increases can offset, compressing margins each year versus the 2025 peak. If this inflationary gap widens beyond what is modeled, combined ratios could deteriorate more severely than the mid-90s normalization path, risking a reset lower in our EPS and price target trajectory. 5. **Lack of explicit forward guidance increases estimate uncertainty**. Management has explicitly declined to provide forward combined ratio targets, with CEO Tom Wilson preferring to 'grow as fast as we can and make as much money as we can' opportunistically rather than commit to specific profitability targets. This lack of guidance increases the risk that consensus and our own model's normalization assumptions diverge materially from actual outcomes, as there is no management anchor to validate the mid-90s combined ratio trajectory assumed in the forecast. 6. **Valuation re-rating risk if peak 2025 earnings are misread as a floor rather than a ceiling**. There is a risk that investors interpret FY2025's $38.19 EPS as a sustainable run-rate rather than a cyclical peak, leading to disappointment and multiple compression as FY2026 net income more than correctly reverts lower to $6.8B. Alternatively, if the market fails to re-rate the stock even as normalized earnings power becomes evident through 2027-2028 results, the anticipated upside to our price targets may not materialize on the timeline assumed, resulting in a value trap scenario despite improving fundamentals.

📈 Price Targets